JP2019506408A5 - - Google Patents

Download PDF

Info

Publication number
JP2019506408A5
JP2019506408A5 JP2018539976A JP2018539976A JP2019506408A5 JP 2019506408 A5 JP2019506408 A5 JP 2019506408A5 JP 2018539976 A JP2018539976 A JP 2018539976A JP 2018539976 A JP2018539976 A JP 2018539976A JP 2019506408 A5 JP2019506408 A5 JP 2019506408A5
Authority
JP
Japan
Prior art keywords
protein
seq
subject
agent
appendix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018539976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506408A (ja
JP6938835B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016120 external-priority patent/WO2017136492A1/en
Publication of JP2019506408A publication Critical patent/JP2019506408A/ja
Publication of JP2019506408A5 publication Critical patent/JP2019506408A5/ja
Application granted granted Critical
Publication of JP6938835B2 publication Critical patent/JP6938835B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018539976A 2016-02-02 2017-02-02 レプチン欠乏状態を治療するためのcd24タンパク質の使用 Expired - Fee Related JP6938835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290202P 2016-02-02 2016-02-02
US62/290,202 2016-02-02
PCT/US2017/016120 WO2017136492A1 (en) 2016-02-02 2017-02-02 Use of cd24 proteins for treating leptin-deficient conditions

Publications (3)

Publication Number Publication Date
JP2019506408A JP2019506408A (ja) 2019-03-07
JP2019506408A5 true JP2019506408A5 (enExample) 2020-03-12
JP6938835B2 JP6938835B2 (ja) 2021-09-22

Family

ID=59500202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018539976A Expired - Fee Related JP6938835B2 (ja) 2016-02-02 2017-02-02 レプチン欠乏状態を治療するためのcd24タンパク質の使用

Country Status (8)

Country Link
US (2) US10799558B2 (enExample)
EP (1) EP3411062B1 (enExample)
JP (1) JP6938835B2 (enExample)
KR (1) KR20180120145A (enExample)
CN (1) CN109069583B (enExample)
CA (1) CA3012466A1 (enExample)
SG (1) SG11201806338SA (enExample)
WO (1) WO2017136492A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799206A (zh) * 2017-05-22 2020-02-14 肿瘤免疫股份有限公司 使用可溶性cd24治疗癌症疗法中免疫相关不良事件的方法
KR20210043483A (ko) * 2018-03-05 2021-04-21 온코이뮨, 아이앤씨. 후천성 면역 결핍 증후군(hiv/aids)을 치료하기 위한 가용성 cd24의 사용 방법
CA3102374A1 (en) * 2018-06-04 2019-12-12 Oncoimmune, Inc. Methods of use of cd24 for the prevention and treatment of leukemia relapse
EP3921339A4 (en) * 2019-02-06 2022-11-09 Oncoimmune Inc. TARGETING CD24-SIGLEC INTERACTIONS TO TREAT PEOPLE WITH PREDIABETES OR DIABETES
WO2020163529A1 (en) * 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE475428T1 (de) * 2000-03-29 2010-08-15 Univ Ohio State Res Found Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen
JP2007504842A (ja) * 2003-05-29 2007-03-08 ミレニアム ファーマシューティカルズ, インコーポレイテッド 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
NZ603196A (en) * 2010-04-28 2014-07-25 Oncolmmune Inc Methods of use of soluble cd24 for therapy of rheumatoid arthritis
KR101982491B1 (ko) * 2011-08-30 2019-05-27 아카데미쉬 메디쉬 센트륨 인슐린 저항 예방 및/또는 치료 방법
KR20150086294A (ko) * 2012-11-05 2015-07-27 프로나이 테라퓨틱스, 인코포레이티드 올리고뉴클레오티드 암 치료제의 복용 및 투여

Similar Documents

Publication Publication Date Title
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
JP7725551B2 (ja) アクチビンiia型受容体変異体を含む医薬組成物
AU2012252153B2 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
JP2015500811A5 (enExample)
JP2025138661A (ja) Fcrn抗体およびその使用の方法
TW200908995A (en) Antibody formulations
AU2012205384B2 (en) IL-27 antagonists for treating inflammatory diseases
ES2926511T3 (es) Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos
JP2019507589A5 (enExample)
ES2655941T3 (es) Proteína de fusión
JP6562912B2 (ja) Cb1受容体抗原結合タンパク質及びその使用
AU2017205343A1 (en) Self-crosslinking antibodies
EP4138998A2 (en) Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the ace2 receptor
NO324206B1 (no) Antistoffer mot interferon alfa-/beta-reseptorer og fremgangsmater for fremstilling og anvendelse derav, samt DNA-molekyl, ekspresjonsvektor, vertscelle, farmasoytisk sammensetning, hybridom og sett.
WO2016019036A2 (en) Recombinant collagen iv surrogates and uses thereof
JP2011032188A (ja) 融合蛋白質
JP5137818B2 (ja) 関節リウマチの処置剤
TW202544038A (zh) 用於治療甲狀腺眼病的方法
WO2000023477A9 (en) Immunoglobulin variants
IL301202A (en) Motile sperm domain containing protein 2 antibodies and methods of use thereof
US20230416378A1 (en) Anti-nrp1a antibodies and their uses for treating eye or ocular diseases
JP2003525040A (ja) 治療用ペプチド
WO2005058358B1 (en) Use of agents derived from ceacam1 for the treatment of inflammatory diseases
CN116333145B (zh) 结合活化凝血因子ix的抗体
CN114409784B (zh) OMgP抗体及其在脊髓损伤中的应用